Selective serotonin re-uptake inhibitors affect craniofacial structures in a mouse model.

Area of Science:

• Developmental Biology
• Pharmacology
• Teratology

Background:

• Selective Serotonin Reuptake Inhibitors (SSRIs) are widely prescribed for mental health conditions.
• Increased SSRI use during pregnancy raises concerns about potential congenital abnormalities.
• Previous studies suggest SSRIs may impact craniofacial development.

Purpose of the Study:

• To investigate the effects of prenatal citalopram exposure on craniofacial and dental development in a mouse model.
• To determine if clinically relevant doses of SSRIs impact embryonic development of the skull and teeth.

Main Methods:

• Utilized a mouse model to mimic in utero exposure to citalopram, a commonly prescribed SSRI.
• Analyzed craniofacial form in postnatal day 15 pups using endocast volume, cranial length, synchondrosis dimensions, and palate measurements.
• Assessed dental development, specifically molar structures.

Main Results:

• Prenatal citalopram exposure led to increased endocast volume, cranial length, and synchondrosis length in mouse pups.
• Decreased growth center (synchondrosis) height/width and palate length/width were observed in SSRI-exposed pups.
• Minimal effects were noted on molar development.

Conclusions:

• In utero exposure to citalopram impacts craniofacial form by altering skull growth sites and centers.
• These findings highlight the potential for SSRIs to influence embryonic craniofacial development.
• Further research is needed to understand the long-term implications of prenatal SSRI exposure on birth defects.